Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Fig 2
Plasma membrane translocation experiments conducted in AKT1-WT and E17K mutant forms of AKT1.
NIH 3T3 cells were transiently transfected with either pcDNAAKT-WT-GFP or pcDNA-E17K-GFP, starved for 24 hours and then were treated with (A) DMSO (B) ARQ 092 or ARQ 751 or (C) MK-2206 or GDC-0068 at 1 μM for 2 hours. After cells were stimulated with PDGF-BB at 50 ng/ml for 10 minutes, membrane translocation of AKT1-WT and AKT1-E17K was detected by a fluorescent microscope.